## J Freedman

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10927691/publications.pdf

Version: 2024-02-01

97	2,915	29 h-index	51
papers	citations		g-index
98	98	98	2025
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The GPIIbIIIa antagonist drugs eptifibatide and tirofiban do not induce activation of apoptosis executioner caspase-3 in resting platelets but inhibit caspase-3 activation in platelets stimulated with thrombin or calcium ionophore A23187. Haematologica, 2009, 94, 1783-1784.	3.5	8
2	In HPA 1a-immunized women the decrease in anti-HPA 1a antibody level during pregnancy is not associated with anti-idiotypic antibodies. Haematologica, 2009, 94, 441-443.	3.5	7
3	Intravenous immunoglobulin products: an update on their mechanisms of action. ISBT Science Series, 2008, 3, 152-158.	1.1	1
4	Higher thrombin concentrations are required to induce platelet apoptosis than to induce platelet activation. British Journal of Haematology, 2007, 136, 762-764.	2.5	52
5	Persistence of procoagulant surface expression on activated human platelets: involvement of apoptosis and aminophospholipid translocase activity. Journal of Thrombosis and Haemostasis, 2007, 5, 560-570.	3.8	32
6	Directions for research in autoimmune thrombocytopenic purpura (ITP). Acta Paediatrica, International Journal of Paediatrics, 2007, 87, 82-84.	1.5	6
7	Rapid clearance of procoagulant platelet-derived microparticles from the circulation of rabbits. Journal of Thrombosis and Haemostasis, 2006, 4, 1621-1623.	3.8	94
8	Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. Journal of Thrombosis and Haemostasis, 2006, 4, 2230-2237.	3.8	89
9	Thrombin-triggered platelet apoptosis. Journal of Thrombosis and Haemostasis, 2006, 4, 2656-2663.	3.8	160
10	Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. Journal of Thrombosis and Haemostasis, 2005, 3, 875-883.	3.8	112
11	Procoagulant surface exposure and apoptosis in rabbit platelets: association with shortened survival and steady-state senescence. Journal of Thrombosis and Haemostasis, 2004, 2, 651-659.	3.8	68
12	Triple heterozygosity in the integrin alphallb subunit in a patient with Glanzmann's thrombasthenia. Journal of Thrombosis and Haemostasis, 2004, 2, 813-819.	3.8	18
13	von Willebrand factor (VWF)-dependent human platelet activation: porcine VWF utilizes different transmembrane signaling pathways than does thrombin to activate platelets, but both require protein phosphatase function. Journal of Thrombosis and Haemostasis, 2003, 1, 337-346.	3.8	10
14	Biological Modification of Lymphocytes in Auto- and Allo-Immune Diseases 1., 2003, , 55-68.		O
15	Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C). American Journal of Hematology, 2002, 69, 192-199.	4.1	10
16	Anti-D (WinRho SD?) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production. American Journal of Hematology, 2002, 69, 225-227.	4.1	35
17	Concurrent measurement of the survival of two populations of rabbit platelets labeled with either two PKH lipophilic dyes or two concentrations of biotin. Cytometry, 2002, 47, 111-117.	1.8	15
18	IVIg inhibits reticuloendothelial system function and ameliorates murine passiveâ€immune thrombocytopenia independent of antiâ€idiotype reactivity. British Journal of Haematology, 2001, 115, 679-686.	2.5	96

#	Article	IF	CITATIONS
19	Interleukins 1beta, 6, 8 and tumour necrosis factor alpha do not induce platelet activation. Transfusion Medicine, 2001, 11, 389-390.	1.1	O
20	Porcine von Willebrand factor and thrombin induce the activation of c-Jun amino-terminal kinase (JNK/SAPK) whereas only thrombin induces activation of extracellular signal-related kinase 2 (ERK2) in human platelets. British Journal of Haematology, 2000, 109, 851-856.	2.5	14
21	Monoclonal antibody-mediated inhibition of the human HLA alloimmune response to platelet transfusion is antigen specific and independent of Fcl <sup>3</sup> receptor-mediated immune suppression. British Journal of Haematology, 2000, 110, 481-487.	2.5	15
22	Comparison of platelet immunity in patients with SLE and with ITP. Transfusion Science, 2000, 22, 19-27.	0.6	37
23	Flow Cytometric Parameters for Characterizing Platelet Activation by Measuring P-Selectin (CD62) Expression: Theoretical Consideration and Evaluation in Thrombin-Treated Platelet Populations. Biochemical and Biophysical Research Communications, 2000, 269, 85-90.	2.1	51
24	Quantification of Platelet Activation Status by Analyzing P-Selectin Expression. Biochemical and Biophysical Research Communications, 2000, 273, 565-570.	2.1	38
25	Antibody-mediated inhibition of the human alloimmune response to platelet transfusion in Hu-PBL-SCID mice. British Journal of Haematology, 1999, 104, 919-924.	2.5	9
26	p38 MAPK is activated but not necessary in porcine von Willebrand factor-dependent platelet activation. British Journal of Haematology, 1999, 107, 532-538.	2.5	15
27	Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura. British Journal of Haematology, 1999, 107, 546-555.	2.5	28
28	Preanalytical requirements for flow cytometric evaluation of platelet activation: choice of anticoagulant. Transfusion Medicine, 1999, 9, 147-154.	1.1	66
29	Inhibition of a secondary human alloimmune response via the soluble active component of CD154 (CD40L) in severe combined immune-deficient mice engrafted with human lymphocytes. Transfusion, 1999, 39, 818-823.	1.6	6
30	Flow cytometric analysis of platelet function in stored platelet concentrates. Transfusion Science, 1999, 20, 129-139.	0.6	52
31	Platelet activation induced by porcine factor VIII (HYATE:C). , 1998, 57, 200-205.		16
32	Characterization of HIV-1-specific antibodies and HIV-1-crossreactive antibodies to platelets in HIV-1-infected haemophiliac patients. British Journal of Haematology, 1998, 103, 1014-1022.	2.5	25
33	The Cellular Immunology Associated with Autoimmune Thrombocytopenic Purpura: An Update. Transfusion Science, 1998, 19, 245-251.	0.6	30
34	Platelet cold agglutinins: a flow cytometric analysis. Transfusion Science, 1998, 19, 217-224.	0.6	13
35	The history of idiopathic thrombocytopenic purpura (ITP). Transfusion Science, 1998, 19, 231-236.	0.6	17
36	Intravenous immunoglobulin and Anti-D in Idiopathic Thrombocytopenic Purpura (ITP): Mechanisms of Action. Transfusion Science, 1998, 19, 289-294.	0.6	44

#	Article	IF	CITATIONS
37	Idiopathic thrombocytopenic purpura (ITP): a historical odyssey. Acta Paediatrica, International Journal of Paediatrics, 1998, 87, 3-6.	1.5	2
38	Reticulated platelet counts in the assessment of thrombocytopenic disorders. Acta Paediatrica, International Journal of Paediatrics, 1998, 87, 65-70.	1.5	8
39	Reticulated platelet counts in the assessment of thrombocytopenic disorders. Acta Paediatrica, International Journal of Paediatrics, 1998, 87, 65-70.	1.5	3
40	Binding of Thrombin to the G-protein-linked Receptor, and Not to Glycoprotein Ib, Precedes Thrombin-mediated Platelet Activation. Journal of Biological Chemistry, 1997, 272, 1997-2004.	3.4	29
41	Induction of a secondary human anti-HLA alloimmune response in severe combined immunodeficient mice engrafted with human lymphocytes. Transfusion, 1997, 37, 1192-1199.	1.6	11
42	Flow cytometric analysis of platelets from childrenwith the Wiskottâ€Aldrich syndrome reveals defects in platelet development, activation and structure. British Journal of Haematology, 1997, 97, 747-754.	2.5	62
43	Pentastarch instead of albumin as replacement fluid for therapeutic plasma exchange. Journal of Clinical Apheresis, 1997, 12, 165-169.	1.3	2
44	Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood, 1996, 87, 4245-4254.	1.4	316
45	Plasmin accelerates plateletâ€dependent prothrombinase formation without activating the platelets. British Journal of Haematology, 1996, 92, 458-465.	2.5	5
46	Characterization of plateletâ€reactive antibodies in children with varicellaâ€associated acute immune thrombocytopenic purpura (ITP). British Journal of Haematology, 1996, 95, 145-152.	2.5	95
47	Platelet-Surface Glycoproteins in Healthy and Preeclamptic Mothers and Their Newborn Infants. Pediatric Research, 1996, 40, 876-880.	2.3	31
48	Applications of flow cytometry in transfusion medicine. Transfusion Medicine Reviews, 1995, 9, 87-109.	2.0	30
49	Abnormal cellular immune mechanisms associated with autoimmune thrombocytopenia. Transfusion Medicine Reviews, 1995, 9, 327-338.	2.0	26
50	Flow cytometric evaluation of platelet activation in blood collected into EDTA vs. Diatube-H, a sodium citrate solution supplemented with theophylline, adenosine, and dipyridamole. American Journal of Hematology, 1995, 50, 40-45.	4.1	52
51	Applications of flow cytometry in the analysis of blood leukocytes. Transfusion Science, 1995, 16, 333-341.	0.6	11
52	Analysis of platelets by flow cytometry. Transfusion Science, 1995, 16, 353-361.	0.6	10
53	Thrombin binding to platelets and their activation in plasma. British Journal of Haematology, 1994, 88, 592-600.	2.5	24
54	The effect of rabbit antithymocyte serum (RATS) and OKT3 on peripheral blood mononuclear cell subsets following renal transplantation. Clinical Transplantation, 1994, 8, 516-22.	1.6	2

#	Article	IF	CITATIONS
55	Idiopathic thrombocytopenia and neutropenia in childhood. The American Journal of Pediatric Hematology/oncology, 1994, 16, 95-101.	1.3	10
56	Prenatal diagnosis of neonatal alloimmune thrombocytopenia using an allele-specific oligonucleotide probe. Prenatal Diagnosis, 1993, 13, 1037-1042.	2.3	14
57	Downregulation of the anti-HLA alloimmune response by variable region- reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates. Blood, 1993, 81, 538-542.	1.4	32
58	Downregulation of the anti-HLA alloimmune response by variable region-reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates. Blood, 1993, 81, 538-42.	1.4	6
59	Cellular Immune Mechanisms in Chronic Autoimmune Thrombocytopenic Purpura (ATP). Autoimmunity, 1992, 13, 311-319.	2.6	15
60	Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood, 1991, 78, 2619-2625.	1.4	167
61	White cell depletion of red cell and pooled random-donor platelet concentrates by filtration and residual lymphocyte subset analysis. Transfusion, 1991, 31, 433-440.	1.6	22
62	Suppressed natural killer cell activity in patients with chronic autoimmune thrombocytopenic purpura. American Journal of Hematology, 1991, 37, 258-262.	4.1	47
63	Simple method for differentiating between HLA and platelet-specific antibodies by flow cytometry. American Journal of Hematology, 1991, 38, 314-320.	4.1	26
64	A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients. Transfusion, 1989, 29, 201-207.	1.6	36
65	Random donor platelet crossmatching: Comparison of four platelet antibody detection methods. American Journal of Hematology, 1988, 28, 1-7.	4.1	25
66	The Significance of Complement on the Red Cell Surface. Transfusion Medicine Reviews, 1987, 1, 58-70.	2.0	25
67	Hemolytic warm IgM autoagglutinins in autoimmune hemolytic anemia. Transfusion, 1987, 27, 464-467.	1.6	21
68	Unexplained periparturient thrombocytopenia. American Journal of Hematology, 1986, 21, 397-407.	4.1	19
69	Autoimmune hemolytic anemia with concurrence of warm and cold red cell autoantibodies and a warm hemolysin. Transfusion, 1985, 25, 368-372.	1.6	11
70	Effect of complement on the viscoelastic properties of human erythrocyte membrane. British Journal of Haematology, 1985, 61, 455-466.	2.5	17
71	Use of the indirect platelet radioactive antiglobulin test with antiâ€igG and anti 3 in immune and nonimmune thrombocytopenias. American Journal of Hematology, 1985, 18, 297-305.	4.1	2
72	Prospective platelet crossmatching for selection of compatible random donors. British Journal of Haematology, 1984, 56, 9-18.	2.5	49

#	Article	IF	Citations
73	Membrane-bound immunoglobulins and complement components on young and old red cells. Transfusion, 1984, 24, 477-481.	1.6	25
74	An unusual autoimmune hemolytic anemia in a patient with immunoblastic sarcoma. American Journal of Hematology, 1983, 14, 175-184.	4.1	8
75	Complement in thrombotic thrombocytopenic purpura. American Journal of Hematology, 1983, 15, 397-398.	4.1	7
76	Red blood cell-bound C3d in normal subjects and in random hospital patients. Transfusion, 1982, 22, 511-514.	1.6	18
77	Red blood cell-bound C3d in selected hospital patients. Transfusion, 1982, 22, 515-520.	1.6	23
78	Parthenocissus tricuspidata Activity Directed against Human Red Blood Cells Coated with C3b. Vox Sanguinis, 1981, 41, 178-182.	1.5	0
79	<i>Parthenocissus tricuspiduta</i> Activity Directed against Human Red Blood Cells Coated with C3b. Vox Sanguinis, 1981, 41, 178-182.	1.5	0
80	Differences in specificities of anti-C3d sera raised to C3d antigens prepared in different ways. Transfusion, 1981, 21, 32-37.	1.6	10
81	Characterization of red blood cells strongly coated in vitro by C3 via the alternative pathway. Transfusion, 1980, 20, 256-262.	1.6	21
82	Assessment of Complement Binding by Anti-D and Anti-M Antibodies Employing Labelled Antiglobulin Antibodies. British Journal of Haematology, 1980, 45, 309-318.	2.5	20
83	Quantitation of C3 subcomponents on red cells coated with complement in vitro. Journal of Clinical Pathology, 1980, 33, 977-983.	2.0	4
84	False-positive antiglobulin tests in healthy subjects and in hospital patients Journal of Clinical Pathology, 1979, 32, 1014-1018.	2.0	29
85	Complement Components Detected on Normal Red Blood Cells Taken into EDTA and CPD <sup>1</sup> . Vox Sanguinis, 1979, 37, 1-8.	1.5	26
86	Crossmatch difficulties following the prophylactic use of Rh immune globulin. Cmaj, 1979, 120, 1235-8.	0.1	0
87	An Immunohematologic Complication of Isoniazid. Vox Sanguinis, 1978, 35, 126-131.	1.5	4
88	An Immunohematologic Complication of Isoniazid. Vox Sanguinis, 1978, 35, 126-131.	1.5	1
89	Autoimmune Haemolytic Anaemia with the Unusual Combination of both IgM and IgG Autoantibodies. Vox Sanguinis, 1977, 32, 61-68.	1.5	0
90	Warm IgM Anti-I^T Causing Autoimmune Haemolytic Anaemia. Vox Sanguinis, 1977, 32, 135-142.	1.5	3

#	Article	IF	CITATION
91	Autoimmune Haemolytic Anaemia with the Unusual Combination of both IgM and IgG Autoantibodies. Vox Sanguinis, 1977, 32, 61-68.	1.5	20
92	Warm IgM Antiâ€I <sup>T</sup> Causing Autoimmune Haemolytic Anaemia. Vox Sanguinis, 1977, 32, 135-142.	1.5	10
93	Further Observations on the Preparation of Antiglobulin Reagents Reacting with C3d and C4d on Red Cells <sup>1</sup> . Vox Sanguinis, 1977, 33, 21-28.	1.5	20
94	Comparison of Lowâ€Molecularâ€Weight Products Following Reaction of C3â€C3b with C3b Inactivator and with Trypsin <sup>1</sup> . Vox Sanguinis, 1977, 33, 212-220.	1.5	14
95	Quantification of antibodies to the C3d subcomponent of human C3. Immunology, 1977, 32, 1007-15.	4.4	8
96	Optimal Conditions for the Use of Sulphydryl Compounds in Dissociating Red Cell Antibodies. Vox Sanguinis, 1976, 30, 231-239.	1.5	39
97	Preparation of Red Cells Coated with C4 and C3 Subcomponents and Production of Antiâ€C4d and Antiâ€C3d. Vox Sanguinis, 1976, 31, 241-257.	1.5	52